syncytial

Ac-CoA Synthase Inhibitor1 (ACSS2 inhibitor) is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2).

RSV604 ((S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea) is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM)

Sisunatovir hydrochloride (RV521 HCl) is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro (IC50 = 1.4 nM for RSV-A, IC50 = 1.0 nM for RSV-B).

Syncytial Virus Inhibitor-1 is a potent, orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion, with EC50 values of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively.

Anti-Human respiratory syncytial virus (RSV) Fusion Glycoprotein/RSV-F Antibody (1B191) is a Rabbit IgG monoclonal antibody targeting RSV Human respiratory syncytial virus (RSV) Fusion Glycoprotein/RSV-F.

Fusion glycoprotein (92-106) [Human respiratory syncytial virus] is a peptide with the sequence H2N-Glu-Leu-Gln-Leu-Leu-Met-Gln-Ser-Thr-Pro-Pro-Thr-Asn-Asn-Arg-OH, MW= 1741.96.

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

(R)-AZD 9639 is the R-isomer of AZD 9639, a novel respiratory syncytial virus (RSV) fusion inhibitor with antiviral activity.

Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.

YM-53403 is an antiviral activity that effectively inhibits the replication of RSV strains belonging to subgroup A and subgroup B. It can be used to treat respiratory syncytial virus infections.

Xibornol (Nanbacine) has broad-spectrum antibacterial and antiviral activity and can be used to study Gram-positive bacterial infections and human respiratory syncytial virus and human coronavirus 229E infections.

JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection.

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde) is an active ingredient of Agastache rugosa.4-Methoxycinnamaldehyde has cytoprotective activity against respiratory syncytial virus (RSV) in human laryngeal carcinoma cell lines, and helps to control disease induced by RSV infection, with an IC50 of approximately 0.055 μg/mL. The IC50 was about 0.055 μg/mL.

RSV-IN-1 is an inhibitor of human respiratory syncytical virus (hRSV) and reduced the virus infectivity with IC50 value of 0.11 μM.

RSV604 R enantiomer is the R-enantiomer of RSV604, a replication inhibitor of respiratory syncytial virus (RSV).

ALS-8112 (ALS 008112) is a selective and potent inhibitor of respiratory syncytial virus (RSV) polymerase with an IC50 value of 0.02 μM. ALS-8112 exhibits antiviral activity and inhibits the RNA polymerase activity of the RSV L-P protein complex through RNA chain termination. virus infections.

Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.

TMC353121 is a respiratory syncytial virus (RSV) fusion inhibitor with anti-RSV activity that inhibits the production of the inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as chemokines, KC, IP-10, MCP, and MIP1-α.

GHP-88309 is an orally active, broad-spectrum anti-paramyxovirus agent that targets viral polymerase, interrupting viral RNA synthesis. It effectively inhibits respiratory syncytial virus (RSV), measles virus (MeV), and canine distemper virus (CDV) with an EC50 of 0.06-1.2 μM. In mouse models, GHP-88309 demonstrates significant anti-infective activity.

RSVL-protein-6 (Compound 19a) is an inhibitor of respiratory syncytial virus (RSV) polymerase, with an IC50 of 13 nM in an SPA primer extension-based enzymatic assay. It is capable of inhibiting RSV replication in HeLa cells.

Rostafuroxin (PST 2238) has been used in trials studying the treatment of Essential Hypertension.